Barry R. Davis, MD, PhD

Dr. Barry Davis, Guy S. Parcel Chair in Public Health, Professor of Biostatistics, and Director of the Coordinating Center for Clinical Trials at The University of Texas School of Public Health, has co-authored more than 300 peer-reviewed publications, and is highly regarded nationally and internationally for his contributions to clinical trials. Show full bio

Dr. Davis has extensive experience in the leadership, design, analysis, oversight, and data management of multicenter clinical trials. He is past President and a Fellow of the Society for Clinical Trials. During the last 30 years, Dr. Davis has participated in and led numerous large-scale cardiovascular (particularly hypertension) clinical trials. Specifically, as PI or Co-I in the NHLBI sponsored Hypertension Detection and Follow-up Program (HDFP), Systolic Hypertension in the Elderly Program (SHEP), Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, a world renowned pragmatic trial), and Genetics of Hypertension Associated Treatment (GenHAT) and in the industry-sponsored Cholesterol and Recurrent Events Trial (CARE).

Dr. Davis’ research has garnered over $200 million in extramural funding. He is a Fellow of the American Statistical Association and the American Association for the Advancement of Science and has served on numerous Data Monitoring Committees.

See Publications



  • Undergraduate:

    Massachusetts Institute of Technology

  • Postgraduate:

    Brown University

  • Medical School:

    University of California San Diego School of Medicine

  • Internship:

    Worcester City Hospital, University of Massachusetts

Academic & Clinical Affiliations

  • The University of Texas School of Public Health


  • American Board of Preventative Health and General Preventative Medicine

Honors, Awards and Memberships


Bidel, Z., Nazarzadeh, M., Canoy, D. et al. (2023). Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention of cardiovascular disease: an individual participant-level data meta-analysis. Hypertension.
Ghosh, A., Chan, W., Younes, N. et al. (2022). A dynamic risk model for multitype recurrent events. Am J Epidemiol, kwac213.
Nazarzadeh, M., Bidel, Z., Canoy, D. et al. (2022). Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol, S2213-8587(22)00172–3.
Kaushal, S., Hare, J. M., Shah, A. M. et al. (2022). Autologous cardiac stem cell injection in patients with hypoplastic left heart syndrome (CHILD Study). Pediatr Cardiol.
Nazarzadeh, M., Canoy, D., Bidel, Z. et al. (2022). The Blood Pressure Lowering Treatment Trialists’ Collaboration: Methodological clarifications of recent reports. J Hypertens.
Canoy, D., Copland, E., Nazarzadeh, M. et al. (2022). Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart, heartjnl-2021-320171.
Du, X. L., Simpson, L. M., Osani, M. C. et al. (2022). Risk of developing Alzheimer’s disease and related dementias in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker with 18 years of follow-up. J Alzheimers Dis Parkinsonism 12, 541
Nazarzadeh, M., Bidel, Z., Canoy, D. et al. (2021). Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet 398, 1803–1810.
Bowling, C. B., Sloane, R., Pieper, C. et al. (2021). Sustained SBP control and long-term nursing home admission among Medicare beneficiaries. J Hypertens 39, 2258–2264.
Woodhouse, L. J., Montgomery, A. A., Mant, J. et al. (2021). Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. BMC Med Res Methodol 21, 218.